Cong Ning

Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

The Illusion of Response: Diffuse Hepatic Metastasis Masked by Shrinking Lesions in Neuroendocrine Carcinoma of the Cervix.

The Illusion of Response: Diffuse Hepatic Metastasis Masked by Shrinking Lesions in Neuroendocrine Carcinoma of the Cervix.

Journal: The American journal of gastroenterology

Published: September 02, 2025

Lenvatinib enhances the response of biliary tract cancer to anti-HER2 therapy.

Lenvatinib enhances the response of biliary tract cancer to anti-HER2 therapy.

Journal: Signal transduction and targeted therapy

Published: July 31, 2025

Stereotactic body radiotherapy plus lenvatinib and sintilimab with and without transarterial embolization for advanced hepatocellular carcinoma with portal vein tumor thrombus: a dual-center, propensity score-matched retrospective analysis.

Stereotactic body radiotherapy plus lenvatinib and sintilimab with and without transarterial embolization for advanced hepatocellular carcinoma with portal vein tumor thrombus: a dual-center, propensity score-matched retrospective analysis.

Journal: Frontiers in immunology

Published: June 09, 2025

Correction: Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer.

Correction: Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer.

Journal: Cancer immunology, immunotherapy : CII

Published: April 21, 2025

Gut microbiota and metabolite signatures predict severe immune-related adverse events in advanced hepatobiliary cancers.

Gut microbiota and metabolite signatures predict severe immune-related adverse events in advanced hepatobiliary cancers.

Journal: Journal of advanced research

Published: September 14, 2024

From Blockage to Passage: Twin Gallstones' Journey Through the Gut.

From Blockage to Passage: Twin Gallstones' Journey Through the Gut.

Journal: The American journal of gastroenterology

Published: August 17, 2024

Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer.

Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer.

Journal: Cancer immunology, immunotherapy : CII

Published: August 05, 2024

Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma.

Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma.

Journal: Journal for immunotherapy of cancer

Published: May 17, 2024

Gut microbiota and metabolites signatures of clinical response in anti-PD-1/PD-L1 based immunotherapy of biliary tract cancer.

Gut microbiota and metabolites signatures of clinical response in anti-PD-1/PD-L1 based immunotherapy of biliary tract cancer.

Journal: Biomarker research

Published: March 21, 2024

Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma.

Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma.

Journal: Biomarker research

Published: September 20, 2023

Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis.

Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis.

Journal: Cancer immunology, immunotherapy : CII

Published: June 30, 2023

The efficacy and safety of bevacizumab as a salvage therapy for patients with advanced hepatocellular carcinoma targeting immune tolerance.

The efficacy and safety of bevacizumab as a salvage therapy for patients with advanced hepatocellular carcinoma targeting immune tolerance.

Journal: American journal of cancer research

Published: May 31, 2023

Showing 1-12 of 24

Last Updated: 09/26/2026